Open an account

Biogen

BIIB · NASDAQ

$243.10+$9.62 (+4.12%)TodayMarket closed ·
Prev close $233.48

About BIIB

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 7,500 full-time employees. The firm is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. The company operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). The company is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. The company also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).

Employees
7,500
Headquarters
Cambridge, Massachusetts
Listed
Sep 17, 1991
Sector
Health Care
Industry
Biotechnology
Website
biogen.com

BIIB key statistics

Market cap
34.50B
Price-earnings ratio
41.47
Dividend yield
—
Average volume
1.23M
Volume
997.63K
Open price
$236.79
High today
$244.65
Low today
$235.96
52 Week high
$240.99
52 Week low
$138.00

Biogen (BIIB) at a glance

As of Oct 20, 2026, Biogen (BIIB) shares are priced at $243.10, giving the company a market cap of 34.50B and a price-to-earnings ratio of 41.47.

Today the stock has traded between $235.96 and $244.65. The current price is 3.0% above the day's low and 0.6% below its high.

Volume so far is 997.63K shares, in line with the average of 1.23M shares a day.

Over the past year Biogen has ranged from $138.00 to $240.99, and now sits 102% of the way up that range.

Biogen met or beat analyst EPS estimates in 8 of the last 8 quarters. In Q2 FY26 it reported $3.60 per share against an estimate of $3.01.

The average analyst price target is $243.16, 0.0% above the current price, from 27 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

63%of 27 analyst ratings say Buy
  • Buy63.0%
  • Hold33.3%
  • Sell3.7%
Price target · 35 analystsAvg $243.16
Low
$176.75
Now
$243.10
High
$315.00

BIIB earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 8 of the last 8 quarters, by 18.9% on average.

  1. Q3 FY24: reported $4.08 per share against an estimate of $3.87
  2. Q4 FY24: reported $3.44 per share against an estimate of $3.42
  3. Q1 FY25: reported $3.02 per share against an estimate of $2.58
  4. Q2 FY25: reported $5.47 per share against an estimate of $3.94
  5. Q3 FY25: reported $4.81 per share against an estimate of $3.96
  6. Q4 FY25: reported $1.99 per share against an estimate of $1.65
  7. Q1 FY26: reported $3.57 per share against an estimate of $2.83
  8. Q2 FY26: reported $3.60 per share against an estimate of $3.01

BIIB news

  • Press releaseGlobe Newswire

    Biogen to Present New Data Across Nephrology Portfolio, Including Long-term EMPAVELI® (pegcetacoplan) Phase 3 Results, at American Society of Nephrology (ASN) Kidney Week

  • Press releaseBusiness Wire

    Stoke Therapeutics Announces Completion of Successful Meeting with the FDA to Align on Planned U.S. NDA for Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome

  • Press releaseGlobe Newswire

    Biogen’s Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 AMETHYST Study, Reinforcing Its Potential as a First-in-Class Therapy for Cutaneous Lupus Erythematosus

  • 10 Health Care Stocks Whale Activity In Today’s Session

  • Press releaseBusiness Wire

    Stoke Therapeutics Appoints Bo Cumbo to its Board of Directors, Enhancing Commercial Expertise as the Company Advances Zorevunersen Development Toward Potential FDA Approval and Commercialization

  • Press releaseGlobe Newswire

    Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-MPGN

  • Press releaseGlobe Newswire

    LEQEMBI® Pen (Subcutaneous Formulation of LEQEMBI®) Approved in Japan for the Treatment of Early Alzheimer’s Disease

  • Press releaseGlobe Newswire

    A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach

Similar companies

Companies in the same industry as Biogen

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.